The Preeclampsia ScreenSM | T1 Screen

The First and Only Screening Test for Early Onset Preeclampsia

Early onset preeclampsia is defined as preeclampsia resulting in the delivery of the fetus before 34 weeks’ gestation. It is estimated to occur in approximately 0.5% of all pregnancies.

Early onset preeclampsia is less common than the late form of the disorder, but contributes more to the morbidity and mortality of pregnant mothers and babies.

Father holding child in air and laughing

Preeclampsia ScreenSM | T1 is an advanced blood test that helps determine your patient’s risk for early onset preeclampsia. Performed between 10 weeks, 0 days and 13 weeks, 6 days gestation, the test combines personal history, ultrasound markers, blood pressure, and analysis of three biological markers  in the patient’s blood to yield a risk assessment.

How It Works

  • People icon

    Demographics:

    The patient’s medical history and demographic information (e.g., height, weight, ethnicity and smoking status) are needed to provide an accurate risk assessment for early onset preeclampsia.

  • Droplet icon

    Biochemical:

    A maternal blood sample is analyzed for three biochemical markers: PAPP-A (pregnancy-associated plasma protein-A); AFP (alpha fetoprotein); and PlGF (placental growth factor).

    Read more about the importance of biochemical markers in prenatal screening.

  • Ultrasound icon

    Biophysical:

    Data from the mean arterial pressure (MAP) and the uterine artery doppler pulsatility are utilized to maximize detection efficiency.

Uterine Artery Doppler Pulsatility Index

Normal First Trimester Uterine Artery Doppler (UtAD)

Normal First Trimester Uterine Artery Doppler

Abnormal First Trimester Uterine Artery Doppler (UtAD)

Abnormal First Trimester Uterine Artery Doppler

Need nuchal translucency or uterine artery doppler pulsatility index certification? We can help.

MAP Protocol

  • Make sure the patient is sitting comfortably with her feet on the floor, legs uncrossed, for about 5 minutes.
  • Blood pressure (BP) measured in both arms simultaneously.
  • Recordings at 1-minute intervals until stable.
  • Enter Left Arm and Right arm BP’s on NTD’s Test Requisition
  • MAP is calculated by NTD Labs.

Detection

EOPE

Detection Rate
False Positive

ASPRE TRIAL

ASPRE trial: Aspirin from 12 weeks
The objectives of this study were to examine if the prophylactic use of low-dose aspirin from the first-trimester of pregnancy in women at increased risk for preterm PE can reduce the incidence of the disease.

“Women should be offered combined screening [i.e. algorithm combining maternal demographics with biochemical & biophysical markers] at 12 weeks, and the high risk group should be treated with aspirin, 150 mg per night, starting from 12 weeks through 36 weeks of pregnancy with a major expected reduction in the rate of preterm preeclampsia.”

– Professor Kypros Nicolaides

Read the full ASPRE article

Test Results

Turn around time: results can be expected 2-5 business days from the time the sample is received at the laboratory.

Learn more about why NTD Eurofins has been the laboratory to trust for over 30 years.

Learn More
Trust

View the complete list of references

Leave the billing worries to us! NTD works hard to ensure that the billing process is simple and easy for your patients.

Interested in sending samples?

We can help you get started!

Contact Us for More Information